UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 260

Sortiert nach

Butaphosphan and Cyanocobalamin Supplementation in Semen Extender on Chilled Boar Sperm Quality and Life Span

Frontiers in veterinary science, 2020-12, Vol.7, p.592162-592162

2020

Volltextzugriff (PDF)

A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells

Genes & cancer, 2010-09, Vol.1 (9), p.908-916

2010

Volltextzugriff (PDF)

Clinical utilities of aromatase inhibitors in breast cancer

International journal of women's health, 2015-01, Vol.7 (default), p.493-499

Chumsri, Saranya

2015

Volltextzugriff (PDF)

Can Breast MRI Select Patients for Treatment With Preoperative APBI?

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S244-S244

2012

Volltextzugriff (PDF)

Preoperative Accelerated Partial Breast Radiation Is Associated With Decreased Cd8+ Cells in Patients With Early Breast Cancer

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S243-S243

2012

Volltextzugriff (PDF)

Near 25% Complete Pathologic Response Following Preoperative Accelerated Partial Breast Radiation Therapy (APBI) Using 3-dimensional Conformal Radiation Therapy (3D CRT)

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S240-S240

2012

Volltextzugriff (PDF)

Equivalent Survival with Breast Conservation Therapy or Mastectomy in the Management of Young Women with Early-stage Breast Cancer

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S32-S33

2011

Volltextzugriff (PDF)

237P Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)

Annals of oncology, 2021-09, Vol.32, p.S462-S463

2021

Volltextzugriff (PDF)

Assessing the Relationship between Residual Cancer Burden and the Tumor Immune-Microenvironment in Early-Stage, Hormone Receptor-Positive Breast Cancer Following Preoperative Radiation Therapy in MC1732 Clinical Trial

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.e11

2022

Volltextzugriff (PDF)

777TiP Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S896

2022

Volltextzugriff (PDF)

Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)

Annals of oncology, 2019-11, Vol.30, p.ix9

2019

Volltextzugriff (PDF)

221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO

Annals of oncology, 2020-09, Vol.31, p.S329-S330

2020

Volltextzugriff (PDF)

Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-11-05

2019

Volltextzugriff (PDF)

Abstract PD3-02: Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD3-02-PD3-02

2019

Volltextzugriff (PDF)

Abstract P2-11-10: Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-11-10

2016

Volltextzugriff (PDF)

Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-08-14

2019

Volltextzugriff (PDF)

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-02-08-OT3-02-08

2019

Volltextzugriff (PDF)

Abstract PD5-2: Preclinical assessment of HDAC inhibitor entinostat combined with all trans retinoic acid (ATRA) in aromatase inhibitor resistant breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.PD5-2-PD5-2

2013

Volltextzugriff (PDF)

Abstract P5-09-05: Progranulin (GP88) expression and letrozole resistance in breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P5-P5-09-05

2013

Volltextzugriff (PDF)

Abstract P1-07-01: Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-07-01

2013

Volltextzugriff (PDF)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer

Breast cancer targets and therapy, 2015-01, Vol.7 (default), p.321-335

2015

Volltextzugriff (PDF)

Abstract P2-04-02: Immunomodulatory effects of entinostat on PD-L1 and MHC class I and II in different subtypes of breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-04-02

2016

Volltextzugriff (PDF)

Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-05

2016

Volltextzugriff (PDF)

Abstract P6-06-01: Improved outcomes with occult versus known primary breast cancer: A SEER analysis

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-06-01

2013

Volltextzugriff (PDF)

Abstract P4-03-05: The Warburg Effect and RUNX2-Regulated Metabolic Switching in Breast Cancer: A New Therapeutic Target?

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P4-P4-03-05

2010

Volltextzugriff (PDF)

1 – 25 von 260

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(237)
Mit Volltextzugriff
(254)

Publikationsform

Sprache

Englisch
(258)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Butaphosphan and Cyanocobalamin Supplementation in Semen Extender on Chilled Boar Sperm Quality and Life Span

A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells

Clinical utilities of aromatase inhibitors in breast cancer

Can Breast MRI Select Patients for Treatment With Preoperative APBI?

Preoperative Accelerated Partial Breast Radiation Is Associated With Decreased Cd8+ Cells in Patients With Early Breast Cancer

Near 25% Complete Pathologic Response Following Preoperative Accelerated Partial Breast Radiation Therapy (APBI) Using 3-dimensional Conformal Radiation Therapy (3D CRT)

Equivalent Survival with Breast Conservation Therapy or Mastectomy in the Management of Young Women with Early-stage Breast Cancer

237P Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)

Assessing the Relationship between Residual Cancer Burden and the Tumor Immune-Microenvironment in Early-Stage, Hormone Receptor-Positive Breast Cancer Following Preoperative Radiation Therapy in MC1732 Clinical Trial

777TiP Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors

Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)

221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO

Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trial

Abstract PD3-02: Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31

Abstract P2-11-10: Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial

Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE)

Abstract PD5-2: Preclinical assessment of HDAC inhibitor entinostat combined with all trans retinoic acid (ATRA) in aromatase inhibitor resistant breast cancer

Abstract P5-09-05: Progranulin (GP88) expression and letrozole resistance in breast cancer

Abstract P1-07-01: Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer

Abstract P2-04-02: Immunomodulatory effects of entinostat on PD-L1 and MHC class I and II in different subtypes of breast cancer

Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies

Abstract P6-06-01: Improved outcomes with occult versus known primary breast cancer: A SEER analysis

Abstract P4-03-05: The Warburg Effect and RUNX2-Regulated Metabolic Switching in Breast Cancer: A New Therapeutic Target?

Suchergebnisse filtern